Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, Molmans BH, Hollema H, Bart J, Drijfhout JW, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW. Vermeij R, et al. Among authors: van der burg sh, van der zee ag. Int J Cancer. 2012 Sep 1;131(5):E670-80. doi: 10.1002/ijc.27388. Epub 2012 Jan 31. Int J Cancer. 2012. PMID: 22139992 Free article. Clinical Trial.
P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.
Lambeck A, Leffers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout JW, Platteel I, Offringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H. Lambeck A, et al. Int J Cancer. 2007 Aug 1;121(3):606-14. doi: 10.1002/ijc.22710. Int J Cancer. 2007. PMID: 17415711 Free article.
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PH, Molmans BH, Hollema H, Drijfhout JW, Sluiter WJ, Valentijn AR, Fathers LM, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW. Leffers N, et al. Among authors: van der burg sh, van der zee ag. Int J Cancer. 2009 Nov 1;125(9):2104-13. doi: 10.1002/ijc.24597. Int J Cancer. 2009. PMID: 19621448 Free article. Clinical Trial.
Potential target antigens for a universal vaccine in epithelial ovarian cancer.
Vermeij R, Daemen T, de Bock GH, de Graeff P, Leffers N, Lambeck A, ten Hoor KA, Hollema H, van der Zee AG, Nijman HW. Vermeij R, et al. Among authors: van der zee ag. Clin Dev Immunol. 2010;2010:891505. doi: 10.1155/2010/891505. Epub 2010 Sep 15. Clin Dev Immunol. 2010. PMID: 20885926 Free PMC article.
Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.
Visser J, van Baarle D, Hoogeboom BN, Reesink N, Klip H, Schuuring E, Nijhuis E, Pawlita M, Bungener L, de Vries-Idema J, Nijman H, Miedema F, Daemen T, van der Zee A. Visser J, et al. Int J Cancer. 2006 May 15;118(10):2529-37. doi: 10.1002/ijc.21673. Int J Cancer. 2006. PMID: 16353143 Free article. Clinical Trial.
Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.
van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter Drijfhout J, Fleuren GJ, van der Zee AG, Melief CJ, Kenter GG, Nijman HW, Offringa R, van der Burg SH. van Poelgeest MI, et al. Among authors: van der burg sh, van der zee ag. Int J Cancer. 2006 Feb 1;118(3):675-83. doi: 10.1002/ijc.21394. Int J Cancer. 2006. PMID: 16108057 Free article.
297 results